image: Insilico Medicine Appoints Man Zhang Ph.D., as Vice President, Head of Biology and Translational Medicine view more
Credit: Insilico Medicine
Nov 28, 2022, New York---Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI) driven drug discovery company, announces that the company has appointed Dr. Man Zhang as Vice President (VP) of Biology and Translational Medicine to lead the biology research team in leveraging its proprietary AI platform to develop target and mechanism research and accelerate novel drug discovery programs. Dr. Zhang will report directly to Dr. Feng Ren, Co-CEO and Chief Scientific Officer of Insilico Medicine.
“We are excited to have Dr. Man Zhang join Insilico to lead biology and translational medicine research,” said Feng Ren, Ph.D., Co-CEO and Chief Scientific Officer of Insilico Medicine. “With her deep knowledge and unique insights in novel drug discovery, Dr. Zhang will expand Insilico's strength in early-stage drug discovery, continue to drive the translation of research discovery into clinical stage, and further accelerate Insilico's pipeline development.”
Dr. Zhang has more than 15 years of experience in drug discovery and translational medicine research. She has worked for domestic and multinational pharmaceutical companies including Hengrui Pharmaceuticals, Johnson & Johnson, and Novartis. Her research covers multiple disease areas including oncology, liver fibrosis, and hepatitis B. She contributed greatly to novel target discovery and mechanism research, as well as promoting novel drug discovery programs.
Prior to joining Insilico, Dr. Zhang served as CSO, Head of Discovery Biology and Translational Medicine at Shanghai De Novo Pharmatech, where she led a comprehensive preclinical team covering discovery biology, translational medicine, and IND-enabling research to advance multiple programs into clinical and IND-enabling studies. During her tenure at Novartis, Dr. Zhang played a critical role in delivering the first-in-class asset MAK683 currently at clinical phase 2.
Dr. Zhang graduated from the University of Texas at Austin with a PhD in 2003. Prior to that, she received her B.S. in Biochemistry and M.S. in Biochemistry and Molecular Biology from Peking University.
“Insilico is one of the pioneering companies in AI-driven drug discovery and development, with impressive achievements in both AI platform development and drug discovery programs,” said Man Zhang, Ph.D., Vice President, Head of Biology and Translational Medicine of Insilico Medicine. “I am glad to join this fast-growing leader in AI-driven drug discovery and work with an experienced drug development team to address the challenges of innovative therapies in the early drug research and clinical stages.”
About Insilico Medicine
Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. http://insilico.com/